145 related articles for article (PubMed ID: 37840156)
1. Urate-Lowering Drugs and Muscle Injury: A Systematic Review and Network Meta-Analysis.
Mitsuboshi S; Morizumi M; Kotake K; Kaseda R; Narita I
J Clin Pharmacol; 2024 Mar; 64(3):288-299. PubMed ID: 37840156
[TBL] [Abstract][Full Text] [Related]
2. Interventions for tophi in gout.
Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
[TBL] [Abstract][Full Text] [Related]
3. The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Zhang S; Xie Q; Xie S; Chen J; Deng Q; Zhong L; Guo J; Yu Y
Pharmacotherapy; 2021 Sep; 41(9):781-791. PubMed ID: 34170566
[TBL] [Abstract][Full Text] [Related]
4. Allopurinol for chronic gout.
Seth R; Kydd AS; Buchbinder R; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006077. PubMed ID: 25314636
[TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat for treating chronic gout.
Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Gupta MK; Singh JA
Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
[TBL] [Abstract][Full Text] [Related]
9. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
Yu X; Gu M; Zhu Y; Zhang L; Kong W; Zou Y
Clin Ther; 2022 May; 44(5):723-735.e6. PubMed ID: 35610080
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
[TBL] [Abstract][Full Text] [Related]
13. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials.
Liu X; Qiu Y; Li D; Tan J; Liang X; Qin W
Front Pharmacol; 2021; 12():690557. PubMed ID: 34413775
[No Abstract] [Full Text] [Related]
15. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
Presa M; Pérez-Ruiz F; Oyagüez I
Clin Rheumatol; 2019 Dec; 38(12):3521-3528. PubMed ID: 31420811
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials.
Xie H; Hu N; Pan T; Wu JC; Yu M; Wang DC
BMC Pharmacol Toxicol; 2023 Dec; 24(1):79. PubMed ID: 38098046
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
18. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
Hill-McManus D; Marshall S; Soto E; Lane S; Hughes D
Value Health; 2018 Dec; 21(12):1373-1381. PubMed ID: 30502780
[TBL] [Abstract][Full Text] [Related]
19. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
Sun SS; Zhang DH; Shi Y; Lin CJ; Lin JY
J Clin Pharm Ther; 2020 Aug; 45(4):729-742. PubMed ID: 32406077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
